FOLR1 and neoplasm: Of note, the humanised mAb-drug conjugate mirvetixumab soravtansine showed promising results in tumours with high FOLR1 expression when assessed in Phase III trials for the treatment of platinum-resistant EOC, but not MOC specifically [78].